GlassScriptPhysician profile
Atul Palkar
NPI 1225326804
$10,009.11
in general payments reported to CMS, 2019-2025
46 companies · $1,753 in 2025
The $1,753 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,975 · 2020: $499 · 2021: $510 · 2022: $2,012 · 2023: $1,588 · 2024: $1,673 · 2025: $1,753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,702 · Education: $313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,701.53 |
| Education | $312.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,876.26 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,201.83 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Pulmonx Corporation | $657.61 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $597.94 | 2019-2025 | Ofev, Jascayd |
| Novartis Pharmaceuticals Corporation | $388.29 | 2019-2025 | |
| Pfizer INC. | $386.17 | 2019-2025 | |
| Genzyme Corporation | $361.41 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $360.28 | 2020-2025 | Glassia, Cuvitru, Hyqvia |
| Actelion Pharmaceuticals US, INC. | $326.96 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Mallinckrodt Hospital Products INC. | $318.68 | 2020-2025 | Acthar |
| Mylan Specialty L.P. | $253.21 | 2019-2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $246.17 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $220.11 | 2019-2024 | Dupixent |
| Grifols USA, LLC | $163.55 | 2019-2025 | Prolastin-C Liquid |
| Amgen INC. | $150.05 | 2022-2025 | Tezspire |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $135.37 | 2021-2025 | Arikayce |
| Electromed, INC. | $121.63 | 2019-2025 | Smartvest |
| Baxter Healthcare | $95.28 | 2022-2025 | Hillrom - Monarch Airway Clearance System |
| Verona Pharma, INC. | $86.94 | 2025 | Ohtuvayre |
| Alexion Pharmaceuticals, INC. | $82.88 | 2019-2023 | Ultomiris |
| Janssen Pharmaceuticals, INC | $78.86 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $78.17 | 2019-2024 | |
| Mallinckrodt Enterprises LLC | $75.81 | 2019 | |
| Optinose US, INC. | $73.32 | 2024 | |
| Merck Sharp & Dohme LLC | $58.75 | 2023-2025 | Winrevair, Keytruda |
| Axsome Therapeutics, INC. | $56.24 | 2025 | Sunosi |
| Zoll Respicardia, INC. | $56.11 | 2025 | Remede System |
| Boston Scientific Corporation | $55.28 | 2022 | |
| Gilead Sciences, INC. | $44.90 | 2022 | |
| Harmony Biosciences LLC | $42.96 | 2020-2021 | |
| Genentech USA, INC. | $40.11 | 2019-2024 | Xolair |
| Csl Behring | $31.32 | 2020-2025 | Hizentra |
| Inspire Medical Systems, INC. | $27.86 | 2025 | Inspire |
| Lilly USA, LLC | $27.53 | 2025 | Zepbound |
| Philips North America LLC | $25.79 | 2022-2023 | |
| Vapotherm INC | $21.63 | 2022 | |
| Inogen, INC. | $21.18 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Resmed Corp | $20.90 | 2025 | |
| Vifor Pharma, INC. | $20.33 | 2024 | Zemaira |
| Azurity Pharmaceuticals, INC. | $20.13 | 2025 | Horizant |
| Abbvie INC. | $20.13 | 2023 | |
| Covis Pharma Gmbh | $19.50 | 2022 | |
| Shire North American Group INC | $18.82 | 2019 | |
| Advanced Respiratory, INC | $17.63 | 2019 | |
| Viatris Specialty LLC | $14.20 | 2025 | Yupelri |
| Ambu INC. | $11.03 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atul Palkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.